Systemic Galectin-3 in Smokers with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis: The Impact of Exacerbations.
Martina SundqvistKristina AndelidAnn Ekberg-JanssonJohan BylundAnna Karlsson-BengtssonAnders LindénPublished in: International journal of chronic obstructive pulmonary disease (2021)
Systemic Galectin-3 is increased in a reproducible but modest manner during exacerbations in smokers with COPD-CB. During stable clinical conditions, the level of systemic Galectin-3 does not distinguish patients that remain clinically stable from those that develop exacerbations. This makes it less likely that systemic Galectin-3 may become a clinically useful biomarker in the current setting.